Omalizumab

奥马珠单抗

Report date: 2026/05/25 20:02:40
First In Class

Base Information

Drug NameOmalizumab
Drug Alias NameMonoclonal antibody E25注射用奥马珠单抗Olizumab奥玛利珠单抗奥马佐单抗 +[20
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionImmunoglobulin E inhibitorsImmunosuppressants
TargetsImmunoglobulin E
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Allergic asthmaSymptomatic Dermographism +[33
Global Approved IndicationsChronic UrticariaAsthma
Approved Indications in ChinaAsthma
Original Approved Country/TerritoryAustralia
Original Approved Date2002/01/01
Country/TerritoryCzechiaBelgiumCanada +[32
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
China Registration ClassN/A

Develop Information

Active IndicationsCoronavirus Disease 2019 (COVID-19)Allergic asthmaChronic rhinosinusitis with nasal polyps (CRSwNP) +[11
Inactive IndicationsSymptomatic DermographismAutism Spectrum DisorderMilk Hypersensitivity +[22

Other Information

ATC CodeR03DX05